Shanghai Novamab Biopharmaceuticals
PrivateLast Round
Series B
Extension
Jul 31, 2024
Total Funding Raised
$66.02M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Shanghai Novamab Biopharmaceuticals is a biopharmaceutical company that develops innovative VHH antibody (nanobody) drugs for respiratory and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai Novamab Biopharmaceuticals Comparables
Compare Shanghai Novamab Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TrueLab Biopharmaceutical | 76% | |
| Sanofi | 74% | |
| Mabgeek Biotechnology | 73% | |
Shanghai Novamab Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jul 31, 2024 | ||||
| Series B | Dec 18, 2023 | ||||
| Series A Extension | Apr 8, 2021 | ||||
| Series A | Mar 12, 2021 | ||||
| Angel | May 13, 2019 |
Key People
Founding team and executive leadership
Shanghai Novamab Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Puhua Capital | Angel |
| Qiming Venture Partners | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 365% MoM.
- May 15, 2026
Monthly visitors increased 178% MoM.
Shanghai Novamab Biopharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Shanghai Novamab Biopharmaceuticals's valuation, stock price, and market status.